Literature DB >> 3014189

Intraocular penetration of new antiviral agent, hydroxyacyclovir (BW-B759U).

J Schulman, G A Peyman, M B Horton, J Liu, J C Barber, R Fiscella, P de Miranda.   

Abstract

9-[(2-hydroxyl-1-(hydroxymethyl)ethoxy]methyl)guanine (hydroxyacyclovir) is a nucleoside analogue with a high degree of efficacy against herpes simplex virus types 1 and 2 and cytomegalovirus (CMV). This antiviral agent demonstrates a low toxicity towards uninfected cells. Intraocular levels in rabbits were evaluated following subconjunctival, intravenous, intravitreal and topical administration. Retinal toxicity studies were performed. Hydroxyacyclovir may have applications in the treatment of deep herpetic infections, CMV retinitis, and acute retinal necrosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014189

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  4 in total

1.  High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration.

Authors:  N Morlet; S Young; D Naidoo; G Graham; M T Coroneo
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

Review 2.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

3.  Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Eperimental toxicity and pharmacokinetics, and clinical trial.

Authors:  M Díaz-Llopis; M J Martos; E España; M Cervera; A O Vila; A Navea; F J Molina; F J Romero
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

4.  Vitreous pharmacokinetics and electroretinographic findings after intravitreal injection of acyclovir in rabbits.

Authors:  Francisco Max Damico; Mariana Ramos Scolari; Gabriela Lourençon Ioshimoto; Beatriz Sayuri Takahashi; Armando da Silva Cunha; Sílvia Ligório Fialho; Daniela Maria Bonci; Fabio Gasparin; Dora Fix Ventura
Journal:  Clinics (Sao Paulo)       Date:  2012-08       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.